Yuanqi Zhao, Yangyang Wan, Xuechun Hu, Xianhong Tong, Bo Xu, Xiaohua Jiang, Shun Bai, Cheng Cao
{"title":"接种SARS-CoV-2疫苗可提高COVID-19康复男性的精液质量：回顾性队列研究","authors":"Yuanqi Zhao, Yangyang Wan, Xuechun Hu, Xianhong Tong, Bo Xu, Xiaohua Jiang, Shun Bai, Cheng Cao","doi":"10.1177/15579883241264120","DOIUrl":null,"url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has been reported to decrease semen quality in reproductive-age men. Semen quality in vaccinated men after SARS-CoV-2 infection remains unclear. We recruited reproductive-age Chinese men scheduled for COVID-19 vaccination from December 2022 to March 2023. Among 1,639 vaccinated participants, an upward trend was found in sperm concentration (<i>p</i> < .001), progressive motility (<i>p</i> < .001), total motility (<i>p</i> < .001), total motile sperm count (TMSC) (<i>p</i> < .001), and normal morphology (<i>p</i> = .01) over time following COVID-19 recovery. Among men with an SARS-CoV-2 infection that lasted less than 30 days, men who received an inactivated vaccine booster had higher sperm progressive (<i>p</i> = .006) and total motility (<i>p</i> = .005) as well as TMSC (<i>p</i> = .008) than those without a booster vaccine, whereas no difference was found in semen parameters among men who received a recombinant protein vaccine. Similarly, an upward trend in semen quality was found among 122 men who provided semen samples before and after COVID-19. Higher risks of asthenozoospermia (odds ratio [<i>OR</i>] = 2.23, <i>p</i> < .001) and teratozoospermia (OR = 2.09, <i>p</i> = .03) were found among men who had an SARS-CoV-2 infection that lasted less than 30 days than among those without COVID-19. Collectively, after receiving SARS-CoV-2 vaccination, adverse but reversible semen parameters were observed in men recovering from COVID-19 over time. Recombinant protein vaccines and inactivated vaccine boosters should be recommended to all reproductive-age men.</p>","PeriodicalId":7429,"journal":{"name":"American Journal of Men's Health","volume":"18 4","pages":"15579883241264120"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282512/pdf/","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 Vaccination Improves Semen Quality in Men Recovered From COVID-19: A Retrospective Cohort Study.\",\"authors\":\"Yuanqi Zhao, Yangyang Wan, Xuechun Hu, Xianhong Tong, Bo Xu, Xiaohua Jiang, Shun Bai, Cheng Cao\",\"doi\":\"10.1177/15579883241264120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Coronavirus disease 2019 (COVID-19) has been reported to decrease semen quality in reproductive-age men. Semen quality in vaccinated men after SARS-CoV-2 infection remains unclear. We recruited reproductive-age Chinese men scheduled for COVID-19 vaccination from December 2022 to March 2023. Among 1,639 vaccinated participants, an upward trend was found in sperm concentration (<i>p</i> < .001), progressive motility (<i>p</i> < .001), total motility (<i>p</i> < .001), total motile sperm count (TMSC) (<i>p</i> < .001), and normal morphology (<i>p</i> = .01) over time following COVID-19 recovery. Among men with an SARS-CoV-2 infection that lasted less than 30 days, men who received an inactivated vaccine booster had higher sperm progressive (<i>p</i> = .006) and total motility (<i>p</i> = .005) as well as TMSC (<i>p</i> = .008) than those without a booster vaccine, whereas no difference was found in semen parameters among men who received a recombinant protein vaccine. Similarly, an upward trend in semen quality was found among 122 men who provided semen samples before and after COVID-19. Higher risks of asthenozoospermia (odds ratio [<i>OR</i>] = 2.23, <i>p</i> < .001) and teratozoospermia (OR = 2.09, <i>p</i> = .03) were found among men who had an SARS-CoV-2 infection that lasted less than 30 days than among those without COVID-19. Collectively, after receiving SARS-CoV-2 vaccination, adverse but reversible semen parameters were observed in men recovering from COVID-19 over time. Recombinant protein vaccines and inactivated vaccine boosters should be recommended to all reproductive-age men.</p>\",\"PeriodicalId\":7429,\"journal\":{\"name\":\"American Journal of Men's Health\",\"volume\":\"18 4\",\"pages\":\"15579883241264120\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282512/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Men's Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/15579883241264120\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Men's Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15579883241264120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
SARS-CoV-2 Vaccination Improves Semen Quality in Men Recovered From COVID-19: A Retrospective Cohort Study.
Coronavirus disease 2019 (COVID-19) has been reported to decrease semen quality in reproductive-age men. Semen quality in vaccinated men after SARS-CoV-2 infection remains unclear. We recruited reproductive-age Chinese men scheduled for COVID-19 vaccination from December 2022 to March 2023. Among 1,639 vaccinated participants, an upward trend was found in sperm concentration (p < .001), progressive motility (p < .001), total motility (p < .001), total motile sperm count (TMSC) (p < .001), and normal morphology (p = .01) over time following COVID-19 recovery. Among men with an SARS-CoV-2 infection that lasted less than 30 days, men who received an inactivated vaccine booster had higher sperm progressive (p = .006) and total motility (p = .005) as well as TMSC (p = .008) than those without a booster vaccine, whereas no difference was found in semen parameters among men who received a recombinant protein vaccine. Similarly, an upward trend in semen quality was found among 122 men who provided semen samples before and after COVID-19. Higher risks of asthenozoospermia (odds ratio [OR] = 2.23, p < .001) and teratozoospermia (OR = 2.09, p = .03) were found among men who had an SARS-CoV-2 infection that lasted less than 30 days than among those without COVID-19. Collectively, after receiving SARS-CoV-2 vaccination, adverse but reversible semen parameters were observed in men recovering from COVID-19 over time. Recombinant protein vaccines and inactivated vaccine boosters should be recommended to all reproductive-age men.
期刊介绍：
American Journal of Men"s Health will be a core resource for cutting-edge information regarding men"s health and illness. The Journal will publish papers from all health, behavioral and social disciplines, including but not limited to medicine, nursing, allied health, public health, health psychology/behavioral medicine, and medical sociology and anthropology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
